IP Library Granted Patent US 10,946,023
Granted Patent B2
US 10,946,023 · App. 16/167,725 · Granted Mar 16, 2021

Therapeutically active compounds and their methods of use

Inventors: Zenon D. Konteatis (Chatham, NJ); Janeta Popovici-Muller (Windham, NH); Jeremy Travins (Southborough, MA); Robert Zahler (Pennington, NJ); Zhenwei Cai (Skillman, NJ); Ding Zhou (Shanghai, CN)
Assignee: Agios Pharmaceuticals, Inc.
A61K31/53A61K31/506A61K31/5377A61K45/06C07D251/18C07D251/48C07D401/04C07D401/14C07D403/04C07D403/10C07D405/12C07D405/14C07D413/04C07D413/14C07D417/04C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,946,023
App. No.
16/167,725
Granted
Mar 16, 2021
Kind
B2
Abstract

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

Claims (70)

1. A method for preparing a compound of formula (Ia) wherein:

ring A is selected from phenyl, pyrazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and thiazolyl, wherein ring A is optionally substituted with up to two substituents independently selected from halo, —C1-C4 alkyl, —C1-C4 haloalkyl, —C1-C4 hydroxyalkyl, —NH-S(O)2-(C1-C4 alkyl), —S(O)2NH(C1-C4 alkyl), —CN, —S(O)2-(C1-C4 alkyl), C1-C4 alkoxy, —NH(C1-C4 alkyl), —OH, —OCF3, —CN, —C(O)NH2, —C(O)NH(C1-C4 alkyl), —C(O)-N(C1-C4 alkyl)2, and cyclopropyl optionally substituted with OH;

R 1 , R 3 , R 4 , and R 6 are each independently selected from hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, —O-C1-C4 alkyl, and CN, wherein each said alkyl moiety of R 1 , R 3 , R 4 , and R 6 are each independently optionally substituted with —OH, —NH2, —CN, —O-C1-C4 alkyl, —NH(C1-C4 alkyl), or —N(C1-C4 alkyl)2;

R 2 and R 5 are each independently selected from: —(C1-C6 alkyl), —(C1-C6 alkyl)-C(O)-NH2, —(C2-C6 alkenyl or alkynyl), —(C1-C6 alkylene)-O-(C1-C6 alkyl), —(C0-C6 alkylene)-C(O)N(R 6 )-C1-C6 alkyl), —(C0-C6 alkylene)-Q and —(C0-C6 alkylene)-C(O)-(C1-C6 alkyl), wherein:

any alkyl or alkylene moiety present in R 2 and R 5 is optionally substituted with one or more —OH, —O(C1-C4 alkyl), —CO2H, or halo;

any terminal methyl moiety present in R 2 and R 5 is optionally replaced with —CH2OH, CF3, —CH2F, —CH2CL, C(O)CH3, C(O)CF3, CN, or CO2H;

Q is selected from carbocyclyl and heterocyclyl, and of which is substituted woth 0-3 instances of halo, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, =O, —C(O)-C1-C4 alkyl, and CN; wherein

R 1 and R 2 are optionally taken together to form a carbocyclyl or a heterocyclyl either of which is optionally substituted with up to 3 substituents independently selected from halo, e.g., fluoro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, —CN, =O, aryl, heteroaryl, —SO2C1-C4 alkyl, —CO2C1-C4 alkyl, —C(O)aryl, and —C(O)C1C4 alkyl; or

R 4 and R 5 are optionally taken together to form a carbocyclyl, or a heterocyclyl either of which is optionally substituted with up to 3 substituents independently selected from halo, e.g., fluoro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, —CN, =O, —OH, aryl, heteroaryl, —SO2C1-C4 alkyl, —CO2C1-C4 alkyl, —C(O)aryl, and —C(O)C1-C4 alkyl;

R 7 and R 8 are H;

comprising a reaction between

2. The method of claim 1 wherein the reaction takes place between 40-120 ° C.

3. The method of claim 1 wherein

is prepared by a method comprising a reaction between

4. The method of claim 3 wherein the reaction takes place between 20-50 ° C.

5. The method of claim 1 wherein

is prepared by a method comprising a reaction between

6. The method of claim 5 wherein the reaction takes place in the presence of a palladium catalyst and a base.

7. The method of claim 6 wherein the palladium catalyst is Pd(PPh3)4.

8. The method of claim 7 wherein the base is K2CO3.

9. A method for preparing a compound of Formula (Ia) wherein:

ring A is selected from phenyl, pyrazolyl, oxazolyl, isoxazolyl, pyridinyl, pyrimidinyl, pyrazinyl, and thiazolyl, wherein ring A is optionally substituted with up to two substituents independently selected from halo, —C1-C4 alkyl, —C1-C4 haloalkyl, —C1-C4 hydroxyalkyl, —NH-S(O)2-(C1-C4 alkyl), —S(O)2NH(C1-C4 alkyl), —CN, —S(O)2-(C1-C4 alkyl), C1-C4 alkoxy, —NH(C1-C4 alkyl), —OH, —OCF3, —CN, —C(O)NH2, —C(O)NH(C1-C4 alkyl), —C(O)-N(C1-C4 alkyl)2, and cyclopropyl optionally substituted with OH;

R 1 , R 3 , R 4 , and R 6 are each independently selected from hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, —O-C1-C4 alkyl, and CN, wherein each said alkyl moiety of R 1 , R 3 , R 4 , and R 6 are each independently optionally substituted with —OH, —NH2, —CN, —O-C1-C4 alkyl, —NH(C1-C4 alkyl), or —N(C1-C4 alkyl)2;

R 2 and R 5 are each independently selected from: —(C1-C6 alkyl), —(C1-C6 alkyl)-C(O)-NH2, —(C2-C6 alkenyl or alkynyl), —(C1-C6 alkylene)-O-(C1-C6 alkyl), —(C0-C6 alkylene)-C(O)N(R 6 )-(C1-C6 alkyl), —(C0-C6 alkylene)-Q and —(C0-C6 alkylene)-C(O)-(C1-C6 alkyl), wherein:

any alkyl or alkylene moiety present in R 2 and R 5 is optionally substituted with one or more —OH, —O(C1-C4 alkyl), —CO2H, or halo;

any terminal methyl moiety present in R 2 and R 5 is optionally replaced with —CH2OH, CF3, —CH2F, —CH2CL, C(O)CH3,C(O)CF3, CN, or CO2H;

Q is selected from carbocyclyl and heterocyclyl, and of which is substituted with 0-3 instances of halo, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, =O, —C(O)-C1-C4 alkyl, and CN; wherein

R 1 and R 2 are optionally taken together to form a carbocyclyl or a heterocyclyl either of which is optionally substituted with up to 3 substituents independently selected from halo, e.g., fluoro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, —CN, =O, —OH, aryl, heteroaryl, —SO2C1-C4 alkyl, —CO2C1-C4 alkyl, —C(O)aryl, and —C(O)C1-C4 alkyl; or

R 4 and R 5 are optionally taken together to form a carbocyclyl or a heterocyclyl either of which is optionally substituted with up to 3 substituents independently selected from halo, e.g., fluoro, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, —CN, =O, —OH, aryl, heteroaryl, —SO2C1-C4 alkyl, —CO2C1-C4 alkyl, —C(O)aryl, and —C(O)C1-C4 alkyl;

R 7 and R 8 are H;

comprising a reaction between

10. The method of claim 9 wherein the reaction takes place in the presence of a palladium catalyst and a base.

11. The method of claim 10 wherein the palladium catalyst is Pd(PPh3)4.

12. The method of claim 11 wherein the base is K2CO3.

13. The method of claim 9 wherein

is prepared by a method comprising a reaction between

14. The method of claim 13 wherein the reaction takes place between 30-60 ° C.

15. The method of claim 13 wherein

is prepared by a method comprising a reaction between

16. The method of claim 15 wherein the reaction takes place between 20-60 ° C.

17. The method of claim 16 wherein the reaction takes place in the presence of a base.

18. The method of claim 17 wherein the base is selected from CsF, NaHCO3, Na2CO3, DIPEA, TEA, pyridine or a combination thereof.

19. The method of claim 18 wherein the base is a mixture of CsF and DIPEA.

20. The method of claim 3 wherein

is prepared by a method comprising a reaction between

and POCl3.

21. The method of claim 20 wherein the reaction takes place at 80-110 ° C.

22. The method of claim 21 wherein

is prepared by a method comprising a reaction between

in the presence of a base.

23. The method of claim 22 wherein the base is an alkoxide base dissolved in the corresponding alcohol.

24. The method of claim 23 wherein the alkoxide is sodium ethoxide dissolved in ethanol.

25. The method of claim 22 wherein the reaction takes place at 20-110° C.

26. The method of claim 20 wherein the reaction additionally takes place in the presence of PCl5.

27. The method of claim 1 wherein R 1 , R 3 , R 4 , and R 6 are each independently selected from hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, —O-C1-C4 alkyl, and CN, wherein each said alkyl moiety of R 1 , R 3 , R 4 , and R 6 is independently substituted with 0-3 instances of —OH, —CN, —O-C1-C4 alkyl, —NH(C1-C4 alkyl), or —N(C1-C4 alkyl)2; and

R 2 and R 5 are each independently selected from: —(C1-C6 alkyl), —(C1-C6 alkyl)-C(0)-NH2, —(C1-C6 alkyl)-CO2H, —(C2-C6 alkenyl or alkynyl), —(C1-C6 alkylene)-O-(C1-C6 alkyl), —(C0-C6 alkylene)-C(O)N(R 6 )-(C1-C6 alkyl), and —(C0-C6 alkylene)-C(O)-(C1-C6 alkyl), wherein:

any alkyl or alkylene moiety present in R 2 and R 5 is substituted with 0-3 instances of —OH, —O(C1-C4 alkyl), —CO2H, or halo; and

any terminal methyl moiety present in R 2 and R 5 can be replaced with —CH2OH, CF3, —CH2F, —CH2Cl, C(O)CH3, C(O)CF3, CN, or CO2H;

R 1 and R 2 can be taken together to form a carbocyclyl substituted with 0-3 substituents independently selected from halo, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, —CN, =O, —OH and —C(O)C1-C4 alkyl; or

R 4 and R 5 can be taken together to form a carbocyclyl substituted with 0-3 substituents independently selected from halo, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, —CN, =O, —OH and —C(O)C1-C4 alkyl;

28. The method of claim 1 wherein ring A is:

wherein R 9 is selected from hydrogen, halo, and —C1-C4 haloalkyl; each X a is independently N or C-R 9a , provided that when one X a is N, then the other two X a are both C-R 9a ; and R 9a is selected from hydrogen, halo, and —C1-C4 haloalkyl.

29. The method of claim 1 wherein ring A is

wherein R 9 is selected from hydrogen, halo, and —C1-C4 haloalkyl.

30. The method of claim 1 wherein R 1 , R 3 , R 4 , and R 6 are each independently selected from hydrogen, C1-C4 alkyl, and —CN, wherein each said alkyl moiety of R 1 , R 3 , R 4 , and R 6 are each independently substituted with 0-1 instances of —OH, —NH2, —CN, —O-C1-C4 alkyl; and R 2 and R 5 are each independently selected from —(C1-C6 alkyl) and —(C0-C6 alkylene)-Q.

31. The method of claim 1 wherein Q is selected from pyridinyl, tetrahydrofuranyl, cyclobutyl, cyclopropyl, phenyl, pyrazolyl, morpholinyl and oxetanyl, wherein Q is substituted with 0-2 substituents independently selected from C1-C4 alkyl, C1-C4 haloalkyl, =O, fluoro, chloro, and bromo.

32. The method of claim 31 wherein Q is cyclopropyl.

33. The method of claim 1 wherein R 1 and R 2 are taken together to form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, oxetanyl, bicyclo[2.2.1]heptanyl, oxobicyclo[3.1.0]hexanyl, azetidinyl, any of which is substituted with 0-2 substituents independently selected from C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, —OH, —C(O)CH3, fluoro, and chloro.

34. The method of claim 1 wherein R 4 and R 5 are taken together to form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyranyl, oxetanyl, bicyclo[2.2.1]heptanyl, oxobicyclo[3.1.0]hexanyl, or azetidinyl, any of which is substituted with 0-2 substituents independently selected from C1-C4 alkyl, C1-C4 alkoxy, C3-C6 cycloalkyl, —OH, —C(O)CH3, fluoro, and chloro.

35. The method of claim 1 wherein the compound is

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME SERVIER PHARMACEUTICALS LLC BY REMOVAL OF COMMA AND UPDATING ZIP CODE TO 02210 PREVIOUSLY RECORDED ON REEL 056224 FRAME 0921. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTIVE ASSIGNMENT. Recorded Oct 28, 2021
From: AGIOS PHARMACEUTICALS, INC.
To: SERVIER PHARMACEUTICALS LLC
Reel/Frame 057970/0314 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 10,172,864 TO THE CORRECT APP NO. 61/160,253 PREVIOUSLY RECORDED ON REEL 056179 FRAME 0417. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 12, 2021
From: AGIOS PHARMACEUTICALS, INC.
To: SERVIER PHARMACEUTICALS, LLC
Reel/Frame 056224/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2021
From: AGIOS PHARMACEUTICALS, INC.
To: SERVIER PHARMACEUTICALS, LLC
Reel/Frame 056179/0417 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2020
From: PHARMARESOURCES (SHANGHAI) CO., LTD.
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 052488/0473 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2020
From: KONTEATIS, ZENON; POPOVICI-MULLER, JANETA; TRAVINS, JEREMY; ZAHLER, ROBERT
To: AGIOS PHARMACEUTICALS, INC.
Reel/Frame 052493/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2020
From: CAI, ZHENWEI; ZHOU, DING
To: PHARMARESOURCES (SHANGHAI) CO., LTD.
Reel/Frame 052488/0219 →
Priority Claims (2)
WO PCT/CN2013/079200 · Jul 11, 2013 · international
WO PCT/CN2014/081957 · Jul 10, 2014 · international
Continuity (3)
Continuation 15392681 · Dec 28, 2016
Continuation 14328885 · Jul 11, 2014
Related Publication 20190117661A1 · Apr 25, 2019